Castaño G, Viudez P, Riccitelli M, Sookoian S

Idioma: Ingles.
Referencias bibliográficas: 23
Paginas: 36-40
Archivo PDF: 111.90 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. García-Pagán J, Escorsell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: basis of its use in the treatment of portal hypertension. Sem Liv Dis 1999; 19: 427-438.

2. Lebrec D. Pharmacological prevention of variceal bleeding. In: Bosch j and Groszmann R, eds. Portal Hypertension pathophysiology and treatment. Oxford: Blackwell Scientific Publications, 1994: 124-139.

3. Feu F, Garccía-Pagán JC, Bosch J, Luca A, Terés J, Escorcell A, Rodés J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-1059.

4. Arroyo V, Bosch J, Mauri M, Ribera F, Navarro-López F, Rodés J. Effect of angiotensin-II blockade on systemic and hepatic hemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981; 11: 221-229.

5. Chiang HT, Cheng JS, Lin M, Tseng WS, Chang JM, Lai KH. Hemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. J Gastroenterol Hepatol 1995; 3: 256-260.

6. Schneider A, Kalk J, Klein C. Effect of Losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334-339.

7. González-Abraldes J, Albillos A, Bañares R, Ruiz del Arbol L, Moitinho E, Rodríguez C, González M, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Ganstroenterology 2001; 121: 382-388.

8. Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, Stoffel-Wagner B, et al. Hemodynamic effects of the Angiotensin II receptor antagonist Irbesartan in patients with cirrhosis and portal hypertension. Ganstroenterology 2001; 121: 389-395.

9. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. Wiley 1981: 38-45.

10. Castaño G, Viudez P, Sookoian S, Carlevaro O, Riccitelli M, Frider B. Propranolol and 5 isosorbide mononitrate in patients with cirrhosis: systemic and portal hemodynamic events. Gastroenterol Hepatol 2000, 23: 275-281.

11. Merkel C, Sacerdoti D, Bolognesi M, Bombonato G, Gatta A. Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment. J Hepatol 1998; 28: 622-630.

12. Castaño G, Viudez P, Carlevaro O, Ocampo C, Zandalazini H, Riccitelli M, Sookoian S, et al. Evaluación de la respuesta al propranolol por cateterismo y ecografía Doppler en pacientes con cirrosis. Acta Gastroent Latinoam 1998; 28: 265-268.

13. García-Pagan JC, Feu F, Bosch J, Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. Ann Intern Med 1991; 114: 869-73.

14. Henriksen J, Moller S, Schifter S, Bendtsen F. Increased arterial compliance in decompensated cirrhosis. J Hepatol 1999: 31: 712-8.

15. Castaño G, Viudez P, Sookoian S, Riccitelli M, Frider B. Effects of Vasoactive Drugs on Arterial Compliance in Cirrhotic Patients. J Hepatol 2000, 2; 32 (suppl 2): 72.

16. Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonat G, Angeli P, et al. Hemodynamic evaluation of the addition of isosorbide-5 mononitrate to nadolol in cirrhotic patients with insufficient response to the b blocker alone. Hepatology 1997; 26: 34-39.

17. Bosch J, Arroyo V, Betriu A, Mas A, Carrilho F, Rivera F, Navarro-Lopez F, et al. Hepatic hemodynamics and the renin angiotensin aldosterone system in cirrhosis. Gastroenterology 1980; 78: 92-99.

18. Bataller R, Gines P, Nicolas JM, Gorbig MN, García-Ramallo E, Gasull X, Bosch J, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-1156.

19. Johnston C. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-1407.

20. Pinzani M, Failli P, Ruocco C, Casini A, Milani S, Baldi E, Giotti A, et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist stimulated intracellular calcium transients. J Clin Invest 1992; 90: 642-646.

21. McIntyre M, Caffe SE, Michalak RA, Reid JL. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997; 74: 181-94.

22. Castaño G, Viudez P, Frider B, Sookoian S. Discussion on randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2002; 122(5): 1544-5.

23. Helmy A, Jalan R, Newby E, Hayes P, Webb D. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 2000; 118: 565-572.